Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Hone, MD
David Hone, Rockville, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20090304750 | NOVEL PRIME-BOOST COMBINATIONS OF ATTENUATED MYCOBACTERIUM - The present invention provides vaccine compositions for effective induction of both mucosal and systemic immunity to pathogenic | 12-10-2009 |
| 20090305398 | Recombinant Double-Stranded RNA Phage, and Use of the Same - A recombinant double stranded RNA (dsRNA) phage expresses dsRNA-encoded genes in eukaryote cells. Recombinant dsRNA phage are useful for the expression of dsRNA expression cassettes encoding passenger genes, such as, but not restricted to, vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Methods are provided to deliver recombinant dsRNA phage to eukaryotic cells and tissues, either by direct administration, formulated in lipid or polylactide-coglycolide, or by utilizing a bacterial vaccine vector. | 12-10-2009 |
| 20110052628 | Recombinant Double-Stranded RNA Phage, and Use of the Same - A recombinant double stranded RNA (dsRNA) phage expresses dsRNA-encoded genes in eukaryote cells. Recombinant dsRNA phage are useful for the expression of dsRNA expression cassettes encoding passenger genes, such as, but not restricted to, vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Methods are provided to deliver recombinant dsRNA phage to eukaryotic cells and tissues, either by direct administration, formulated in lipid or polylactide-coglycolide, or by utilizing a bacterial vaccine vector. | 03-03-2011 |
David Hone, Poolesville, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20090123492 | GENERATION OF NEW BCG VACCINE STRAINS PROTECTING AGAINST THE ESTABLISHMENT OF LATENT MYCOBACTERIUM TUBERCULOSIS INFECTION AND REACTIVATION FROM THE LATENT OR PERSISTENT STATE - A vaccine for treating or preventing the establishment of latent tuberculosis infections is provided. The vaccine comprises a recombinant | 05-14-2009 |
| 20100322951 | Replication-proficient dsRNA capsids and uses thereof - Compositions and methods useful in the production of proteins in vitro and in vivo are provided. In particular, this invention provides bionanoparticles comprised of replication-proficient, double-stranded RNA (dsRNA) capsids which are capable of transfecting, for example, target bacterial, yeast, plant and mammalian cells, and causing expression of genes of interest in said transfected cells. The bionanoparticles comprised of replication-proficient, dsRNA capsids are also capable of expressing genes of interest in vitro. The genes of interest can encode proteins that are useful, for example, as research reagents, therapeutics and vaccines. Also described are methods that enable the construction of bionanoparticles comprised of replication-proficient dsRNA capsids and methods for transfecting cells with said bionanoparticles and expressing said genes of interest in transfected cells and in vitro. | 12-23-2010 |
David Hone, Bethesda, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20090123438 | Multivalent Vaccines Comprising Recombinant Viral Vectors - The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. The invention also relates to the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. The invention furthermore relates to the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease. | 05-14-2009 |
David M. Hone, Rockville, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20100047286 | Recombinant BCG strains with enhanced ability to escape the endosome - strains that have an enhanced ability to elicit a Histocompatibility-Class I-restricted CD8 | 02-25-2010 |
David Michael Hone, Rockville, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20080286852 | Electroporation of Mycobacterium and Overexpression of Antigens in Mycobacteria - Recombinant | 11-20-2008 |
| 20100233213 | Recombinant BCG Strains with Enhanced Ability to Escape the Endosome - strains that have an enhanced ability to elicit a MHC-Class I-restricted CD8 | 09-16-2010 |